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Fixed eruptions produced by the arsphenamines are apparently
identical in every respect, except for the drug implicated, with
eruptions of a similar type produced by other drugs, notably
phenolphthalein, antipyrine and the barbiturates. The excep-
tion is vital since testing with the specific drug is the only conclu-
sive means that we now possess of determining the drug respon-
sible for a given fixed eruption. We agree with Abramowitz and
Noun (1) that the expression "fixed" does not refer to the dura-
tion or persistence of the lesion, nor to its residual pigmentation,
but solely to the fact that a previously affected area can be ac-
tivated by the drug in question. Or, as expressed by Naegeli (2),
it is a reaction exhibiting a local biologic difference in tissues
which are anatomically and functionally identical
As is well known, the term fixed drug eruption was introduced
by Brocq (3) in 1894 to describe a characteristic cutaneous lesion
produced by antipyrine. The first application of this descriptive
phrase to similar eruptions associated with the arsphenamines
was made by Naegeli (4). In the American literature, it was
already mentioned as early as 1919 (5).
The present communication deals with a group of 69 patients,
all syphilitic, who, in the course of treatment with the organic
arsenicals, developed a fixed eruption. Sixty-eight of these pa-
tients had fixed eruptions which were proved to be initiated by
one or another of the trivalent organic arsenicals. One of these
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had a double sensitivity of the fixed eruption type, that is not
only to the arsenicals, but to phenolphthalein as well. The last
patient was sensitive to antipyrine, but not to the arsenicals.
This group of patients has been observed over a variable period
of time, many as long as 4 years. The duration of the syphilitic
infection, when the eruption was first noticed, was as short as
one month and as long as 26 years. In age, the patients varied
from 20 to 57 years, the majority were between 20 and 35 years.
Not a single instance was observed in children with congenital
or acquired syphilis; these represent, however, but a small per-
centage of our clinic clientele.
A definite predisposing factor to this type of eruption, at least
in the case of the arsenicals, seems to be the race of the patient.
In the series of 68 patients, 54 (79%) were negro, 13 (19%)
white, and 1 (2%) yellow. In our clinic, 54% of the patients
treated are negroes, and 45% are whites; this shows a definite
preponderance of this eruption in the negro race. Insofar as sex
may be a factor, the series revealed 38 (55%) males and 30 (45%)
females, while our general clinic attendance is approximately
62% males and 38% females.
The initiating drug in 58 (85%) patients was arsphenamine, in
5 (7%) neoarsphenamine, in 2 (3%) mapharsen, in 2 (3%) silver
arsphenamine, and in 1 (2%) trisodarsen. However, it must be
borne in mind that the routine drug used in our clinic is arsphen-
amine, and this perhaps accounts for the preponderance of cases
initiated by this drug.
The eruption was noted in one instance after the second injec-
tion of the arsenical, but never after the first dose. In one case
it was first observed after the 89th arsenical injection. However,
30 (44%) of the cases occurred between the 10th and 20th dose,
and 49 (72%) appeared between the 10th and 30th dose. Only 9
(13%) instances occurred with less than 10 doses of an arsenical.
DESCRIPTION OF LESIONS
From a morphologic standpoint we have not been able to dis-
tinguish arsphenamine fixed eruptions from those due to phenol-
phthalein, antipyrine and the barbiturates. The individual
lesions may be very small (2—3 mm.) or large 6—8 cm.). They
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are discrete and do not as a rule coalesce; they may be few or
numerous. They are round or oval in outline. When the lesion
first appears it is usually as an erythematous macule, or far more
rarely urticarial in type. The common form, the erythematous
macule, shows varying degrees of redness, from a faint pink to
an intense red, and in the latter instance may be accompanied
by edema and vesiculation, or bulla formation, eventuating in
desquamation. When the acute phase subsides there is usually
residual pigmentation. This is especially true in the negro, and
the degree of pigmentation may be said to be more or less pro-
portionate to the normal pigment content of the individual's
skin. So, in blondes there may be no clinically visible pigmenta-
tion, while in brunettes and mulattoes the pigmentation may be
moderate, and in the full-blooded negro, the color may be almost
ebony black. There is a progressive tendency towards intensi-
fication of pigmentation as a result of repeated activation of the
lesions with the arsenical. As in the case with phenolphthalein
and antipyrine, repeated administration of the drug, when reac-
tion ensues, not only produces a flare-up in the lesion itself, but
also a corona of redness, immediately about the lesion, usually
narrow in width. In this manner the size of the lesion is in-
creased, since the coronal zone subsequently becomes part of the
original lesion and also becomes pigmented. This increase in
size of the lesion has however, limitations beyond which no fur-
ther enlargement occurs. Whether this is due to local immunity,
or to the attainment of tissues incapable of the reaction, we are
not prepared to state. In many cases, where the arsenicals are
discontinued, there is a gradual tendency for the pigmentation
to fade, but this requires long periods of time, even years. In the
white race the pigment fades rather rapidly, at times in a few
weeks.
The urticarial type of fixed eruption does not apparently have
the same power of inducing residual pigmentation as the erythe-
matomacular variety. This may be due to the different location
of the pathological process. In the few cases observed by us,
the urticarial lesions were limited to the face, and were single or
few in number.
With regard to location, there is a definite predilection for the
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face, particularly around the mouth and including the vermilion
surface of the lip; also, to a lesser extent, around the eyes with
involvement of the eyelids. However, lesions are often observed
on the neck, trunk, arms, legs and more rarely on the genitals,
dorsa of hands and feet, but we have never encountered them on
the scalp, palms and soles. One of the patients had lesions of
the mucous membranes, as well as a typical skin eruption. She
presented a mildly pigmented patch with an erythematous border
on the tip of the tongue.
We have one instance in which the eruption was limited to the
mucous membranes of the mouth. The lesions were located on
the tongue, the inside of the lower lip, and the right buccal
mucosa, and on 3 occasions these sites flared up when the drug
(trisodarsen) was administered. The lesions were erythematobu1-
bus in type. No lesions were present elsewhere on the body.
The patient was a negro male. The eruption was produced by
trisodarsen, and attempts to elicit it with arsphenamine, neo-
arsphenamine, mapharsen, tryparsamide, acetarsone, phenol-
phthalein and antipyrine failed.
Despite evident clinical reaction, there may be no subjective
symptoms, but usually there are varying grades of itching and
burning, often in proportion to the intensity of reaction. Fre-
quently the only reaction is a subjective one, with itching or
burning, but without clinically visible change in the appearance
of the lesion. This is the mildest form of reaction observed, and
is especially noted in patients who are weak reactors even with
large doses of the drugs.
Table 1 gives details of tests performed with various drugs.
The table includes 68 patients who had arsphenamine fixed erup-
tions, one of whom at the same time had lesions produced by
phenolphthalein, and also one patient who reacted to antipyrine
and not at all to the arsenicals.
(1) Case with double sensitivity
This patient (6), a white female age 35, was treated with ars-
phenamine for late latent syphilis. After the 19th injection a
fixed eruption appeared. Subsequent testing showed her to be
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positive also to neoarsphenamine, acetarsone and trisodarsen, but
not to silver arsphenamine and sulfarsphenamine. Tests with
other drugs which produce fixed eruptions showed sensitivity to
phenolphthalein, but in different areas from those affected by
arsphenamine. The arsphenamine-sensitive areas are located
chiefly on the left arm, while the phenolphthalein-sensitive areas
are on the right side of the neck and the right arm. The patient
is not sensitive to antipyrine.
It should be noted that there was no difference in the clinical
appearance of the lesions produced by arsphenamine and phenol-
TABLE 1
ROUTE OF NUMBER OF ITIVE NEGATIVDRUG ADMINISTRA- CASES REACTORSlION TESTED
Arsphenamine I.v. 68 66 (97%) 2 (8%)
Neoarsphenamine I.v. 65 63 (97%) 2 (3%)
Silver arsphenamine Lv. 50 45 (90%) 5 (10%)
Mapharsen I.v. 51 36 (70%) 15 (30%)
Trisodarsen I.v. 19 13 (68%) 6 (32%)
Sulfarsphenamine Lm. 44 34 (77%) 10 (23%)
Acetarsone Oral 60 39 (65%) 21 (35%)
Aldarsone I.v. 11 5 (45%) 6 (55%)
Tryparsamide I.v. 31 0 31 (100%)
Fowler's 8olUtion Oral 67 0 67 (100%)
Sodium cacodylate Lv. 2 0 2 (100%)
Phenolphthalein (1) Oral 69 1 68
Antipyrine (2) Oral 69 1 68
phthalein, and that the only way they could be differentiated was
by the specific reaction to the drug.
() Case sensitive to antipyrine
This patient was a colored male, 23 years old, who received
antisyphilitic therapy for early latent syphilis. While under
treatment, after the 12th dose of mapharsen, a fixed eruption was
noted. At first it was accredited to the arsenical, but when he
was retested with mapharsen and with 5 other trivalent arsenicals
and found negative to all, another source was sought. Phenol-
phthalein was negative, but repeated tests with antipyrine pro-
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yoked marked reactions in the fixed eruptions. It was then
learned that he had been taking a proprietary medication which
contained antipyrine.
This case illustrates the necessity for careful inquiry and testing
in all cases of fixed eruptions, even in patients receiving the
arsenicals.
PATCH TESTS
In addition to the tests performed by administration of the
drugs intravenously, orally and intramuscularly, as detailed in
table 1, patch tests were also performed. They were done in
17 patients, using arsphenamine in 0.5% aqueous solution, and
neoarsphenamine in 5.0% aqueous solution. These tests were
performed in normal skin areas as well as over fixed eruption sites,
and were negative in every instance.
IONTOPHORESIS'
lontophoresis was done in 9 patients, in 8 with arsphenamine
in concentrations from 0.5% to 5.0%, and in 1 with neoarsphen-
amine in 5.0% concentration; the current varied from 0.5 to 2
milliamperes, and the exposure time was between 10 and 15
minutes. All gave negative reactions, except 1 patient in whom
a faint redness appeared at the border of the lesion. We consider
this a very doubtful reaction, and more likely due to the current
used (2 milliamperes for 15 minutes).
DESENSITIZATION WITH ADRENALIN
In an attempt to prevent the activation of the eruption, as
suggested by Naegeli (2), we gave 9 patients a subcutaneous
injection of 10 minims of adrenalin shortly before the intravenous
arsenical was administered. In 6 patients there was a prompt
activation of the eruption, in the remaining 3, no reaction ensued.
However, a study of the records of these 3 patients reveals the
fact that they were in a refractory phase and this probably
accounts for the failure to react.
1 These tests were performed with the assistance of Dr. Naomi M. Kanof and
Dr. J. Churg.
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ATJTOTRANSPLANTS
In 3 patients autotranspiants were performed in an effort to
determine whether it is possible to transfer the shock tissue to
normal sites and to transfer normal tissue to shock tissue sites.
The first, H. F., a colored male, 41 years old, had an extensive
fixed eruption of variously sized lesions, distributed on the face,
trunk and extremities. The eruption, first appeared after the
14th arsphenamine injection and subsequently the patient reacted
to neoarsphenamine, mapharsen, silver arsphenamine, sulphars-
phenamine, acetarsone and aldarsone. He did not react to liquor
potassi arsenitis, antipyrine, phenolphthalein, tryparsamide and
trisodarsen, and was negative to patch tests with arsphenamine
and neoarsphenamine.
With the cooperation of Dr. M. B. Sulzberger, a transplant
was performed by the department of plastic surgery of the Post-
Graduate Hospital. A well-marked lesion on the thigh, about
3 cm. in diameter, was transplanted by full-thickness graft, to a
normal area at a corresponding site on the opposite thigh. The
tissue from the normal site was transferred to the site of the fixed
eruption. Both transplants healed by primary union, showing
mild pigmentation at the border of the transplants. The fixed
eruption transplant retained a considerable part of its previous
hyperpigmentation. In both transplanted areas touch and pain
(pinprick) sensations were markedly diminished although the skin
in other respects seemed normal.
During the 3 year period subsequent to this operative pro-
cedure, repeated tests were performed with the drugs to which
the patient was sensitive; these were administered in various
dosages, and at varying intervals of time. All gave negative
results in both transplants, but characteristic responses in many
of the other lesions on the body.
In 2 additional cases we performed sliding full-thickness grafts,
by excising a considerable portion of the fixed eruption site and
sliding into this area normal adjacent skin. Healing took place
by primary union. Repeated testing of these 2 patients gave
reactions in all areas of fixed eruptions but failed to cause a reac-
tion in the normal skin shifted into the fixed eruption site.
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REFRACTORY PERIOD
It has long been noted that patients suffering from fixed erup-
tions caused by phenolphthalein and antipyrine have refractory
periods (negative phase, tissue exhaustion), (7) that is, the offend-
ing drug fails to activate the lesions. The reason for this 1os of
sensitivity is unknown. Such refractory periods have also been
observed with the arsphenmines and appear to he of 2 types.
In the first type, there is a temporary loss of sensitivity to a
single member of the group of trivalent arsenicals. An exanipk
of this type of refractory phase is patient J. L., white male 37
years old, who had reacted to neoarsphenamine 0.2 gm. on several
occasiolls. From 9/22/36 until 2/23/37 he received neoarsphen-
amine 0.2 gm. once, 0.3 gm. twice and 0.4 gm. once, all without
any reaction. During this period of time he had consistently
reacted to arsphenamine, mapharsen and silver arsphenamine.
On 2/23/37 he was given neoarsphenamine 0.3 gm. with the
production of typical reaction in the lesions.
In the second type, there is a temporary loss of sensitivity to
all members of the group over a period of weeks to months.
Exemplifying this type of refractoriness is D. C., negro male,
57 years old, who reacted to arsphenamine, neoarsphenamine and
silver arsphenamine. From 10/13/36 until 11/23/37 he was
given 6 injections of arsphenamine (0.1—0.3 gm.), 10 injections
of neoarsphenamine (0.2-0.3 gm.), 5 of silver arsphenamine
(0.15-0.2 gm.), and 5 of mapharsen (0.02—0.06 gm.) without any
activation of the lesions. The patient returned in June 1939,
after an absence of 18 months; tests were made with neoars-
phenamine 0.35 gm. and mapharsen 0.04 gm. to both of which he
reacted strongly.
There is still another type, in which the lack of response may
be incorrectly regarded as a refractory period, but where the
failure is due, we believe, rather to inadequate dosage than to
loss of ability to react. A considerable number of cases when
given a dose of the arsenical without reaction, would have a char-
3.-,/7-../2
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acteristic response a few days later, when the same arsenical was
given in higher dosage. For example, one patient who had
reacted consistently to arsphenamine 0.2 gm. was given 0.025 gm.
without any reaction; a week later he was given 0.05 gm. again
without reaction; the following week he was given 0.075 gm. and
reacted. The next week the dosage was dropped to 0.05 gm.
and there was no reaction. This at least suggests the necessity
for considering dosage as a factor in the subject of refractoriness.
FIG. 1
A number of eases, illustrative of the various forms of negative
response described above, have been observed. It should be
pointed out that not every patient had a refractory period, in
fact 47 of the 68, i.e., 70% of the cases reacted at all times when
tested. It is also to be noted that many of the patients with
periods of refractoriness were weak reactors at all times; this again
suggests that dosage may play a role in the entire problem of
refractoriness.
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HISTOPATHOLOGICAL STUDIES (SLIDES STUDIED AND REPORTED BY
DR. S. M. PECK)
Case 1. J. M., brunette, age 27, biopsy taken 1/6/40.
Biopsy taken so that a large section of normal skin is included.
A. H & E Stain (Fig. 2) (area of drug eruption): There is a moderate hyper-
keratosis. The basal cell layer shows marked intracellular edema and also some
intercellular edema not unlike that seen in lichen planus. Just below the epi-
dermis there are a great many chromatophores, loaded with pigment. These are
FIG. 2
seen singly for the main part, and are situated around blood vessels. Many of the
blood vessels are dilated and suggest telangiectasia. Pigment lies free in the
corium as well as within the chromatophores. There is a little perivascular
inflammatory reaction outside of the masses of pigment. Such inflammatory
reaction as is seen, consists mainly of lymphocytes.
B. Hematoxylin and Silver PMG Stains (Fig. 3) (Von Kossa): It is very
striking to observe that the basal cells in the non-pigmented area, clinically non-
affected skin surrounding the pigmented area, contain more pigment than those
in the drug eruption site. The pigment in the basal cells is seen in the form of fine
granules situated around the nucleus. No dendritie cells are seen. The ehro-
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tion, is markedly accentuated by the Silver stain, and forms dense clumps right
below the epidermis and in the upper cutis; free pigment is also seen.
C. Iron Stain (Fig. 1). Iron stain is negative.
D. Dopa reaction: The dopa reaction in pigmented skin as well as normal skin
was practically negative. Active pigment formation has stopped.
Case 2. H. L., mulatto, age 27, biopsy taken 1/18/40.
A. H & E Stain: Moderate hyperkeratosis. The epidermis seems normal ex-
cept for some intercellular edema. The papillary and sub-papillary bodies show
FIG. 3
edema, mostly in the papillary bodies. The vessels are dilated and there is a
moderate amount of perivaseular infiltration.
B. Silver Stain: There is a great deal of pigment throughout the epidermis,
mostly in the basal layer, but also some being east off with the scales. A great
deal of the pigment in the eutis is situated especially in the papillary layer, but
there is also some in the sub-papillary layers. It is for the most part in ehro-
matophores, but also as free clumps in the tissues. A great deal is found around
the capillaries in the papillary and sub-papillary layers.
C. Iron Stain: The iron stain is negative and the pigment masses are evidently
melanin in the chromatophores and free in the tissue. Here and there a positive
iron stain is seen but this does not correspond to the great mass of pigment.
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D. Dopa reaction (Fig. 4): The dopa reaction is moderately positive in many
of the basal cells. Cells with short dendrites are seen. As one passes along the
epidermis into apparently normal skin, the dopa is less positive than in those
areas in which there is ehromatophorie pigment. Apparently more active pig-
ment formation is taking place in the area of drug eruption, than is in the center
of the slide.
Case 3. F. G., white, age 51, biopsy done 2/17/40.
A. H & E Stain (Figs. 5 & 6): One part of the slide is apparently the area of
fixed eruption and shows moderate hyperkeratosis, some patchy areas of inter-
FIG. 4
and intracellular edema, very moderate in amount. In places there is actual
microscopic vesicle formation, with some leukoeytie infiltration of the epidermis.
In the papillary and sub-papillary bodies there are many dilated capillaries form-
ing what can almost be said to be telangieetasia. These are filled with blood, and
show surrounding edema and perivaseular infiltration especially with mononu-
clear cells and some leukoeytes. This type of inflammatory reaction extends to
a lesser degree into the normal areas.
Pigment is seen free in the tissues, but also in ehromatophores situated around
blood vessels. The difference between the area of fixed eruption and normal skin
is largely in the quantity of perivascular pigment and dilated vessels.
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FIG. 5. CENTER OF FIXED ERUPTION
FIG. 6. NORMAL MARGIN OF FIXED ERUPTION
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the section shows melanin in the eutis which gradually diminishes until practically
none is seen either in the eutis or in the epidermis. The greatest amount of pig-
ment is seen at the margin of the fixed eruption towards the normal skin, which
contains as much or more pigment in the epidermis than the fixed eruption site
itself.
The epidermis contains relatively few dendritic cells. The pigment-contain-
ing basal cells are the ordinary basal cell forms. It is very striking here that that
part of the section, which macroseopically appeared to be normal skin, histo-
Fin. 7
logically, for quite a distance, shows a similar process as in the area of drug
eruption, but quantitatively diminished.
C. Iron Stain: Iron stain is negative.
D. Dopa reaction: The dopa reaction is positive in isolated cells and nearly
nil in dendritic forms (in other words we have a moderate Dopa reaction which
is of greater intensity over areas of increased chromatophorie pigment).
SUMMARY OF HISTOPATHOLOGICAL FINDINGS
Evidently the histologic findings of fixed eruptions due to the
arsphenamines and those produced by phenolphthalein or anti-
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pyrine are similar. The changes are found in the epidermis and
upper part of the cutis, especially around the blood vessels. In
the epidermis there is evidence of increased pigment formation
and edema of the cells. The pigment is dropped into the cutis
and is then seen in chromatophores and free in the tissue. The
vessels in the upper cutis are increased in number and especially
in size and show a mantle of chromatophoric pigment. The
dropping of pigment resembles that seen in lichen planus.
The pigment is almost wholly melanin, only faint rare traces
of iron being present, indicating that hemorrhage, if present, is a
minor accompaniment. Pigmentation persists for long periods
because so much of the pigment is found extracellularly. The
pathology shows that the inflammatory process extends beyond
the clinically involved areas, that is, the tissue beyond the active
area to an extent is subclinically active. It thus explains the
extension of the process when the drug is again administered.
The color of the lesion seems to be due to dilatation of the blood
vessels and the chromatophoric pigment. Microscopic study
shows that the amount of pigment in the fixed eruption area is
quantitatively less in whites than in negroes.
COMMENT
Fixed eruptions are certainly not common in the course of anti-
syphilitic therapy, yet they occur with sufficient frequency to be
of practical importance. This is especially true in cases of early
syphilis, where therapy with the trivalent arsenicals may for this
reason alone have to be interrupted. Furthermore, the frequent
location of lesions on the face is a cosmetic blemish which makes
patients reluctant to accept further therapy in any stage of
syphilis. While our experience shows that not all the arsenicals
are equally guilty, they have all been found capable of either
producing or activating the eruption.
At first glance one would imagine that the number of fixed
eruptions in our clinic is inordinate, but one can account for this
on two bases, one, that a large number of patients are under
treatment in this clinic (in the 4 year period of this study, over
16,000 patients received treatment), and two, that the condition
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is far more common in negroes than whites and in our clinic
negroes constitute 54% of the clientele. It is our belief that
cases of this variety especially when there are only a few lesions
present (in the negro particularly) escape notice.
It is to be stressed that not all pigmented lesions due to arsenic
are of the kind under discussion. For example, arsenical melano-
sis, especially of the so-called "spotted variety"; and the variety
which follows lichenoid or generalized arsenical dermatitis, bear
no relation to the eruption under discussion.
There is no doubt that arsenical fixed eruptions occur only
when the drug reaches the skin through the blood stream, al-
though the drug is introduced by one of the following routes,
intravenous, oral or intramuscular. Once the eruption is present,
it can only be activated when the drug again reaches the skin
hematogenously, however introduced, and never by external
application as in patch tests or by electrophoretic methods.
In reviewing the literature one finds a certain basic discrepancy
in results obtained with autotranspiants. Thns, Naegeli (2),
Urbach et a!. (8) found that with superficial (Thiersch) grafts,
the healthy skin transplanted into the fixed eruption site did not
react, while the fixed eruption skin transplanted to a healthy site
did react. This would suggest an epidermal sensitivity rather
than a sensitivity of deeper structures.
On the contrary, Wise and Sulzberger (9), Loveman (10),
Knowles et al. (11), all of whom did full-thickness transplants,
obtained diametrically opposite results, namely, the healthy skin
transplanted to the site of a fixed eruption did react, while the
fixed eruption skin transplanted to a healthy site failed to do so.
This finding indicated to the experimenters that the sensitivity
lay deeply in the skin, possibly in the blood vessels and/or nerves.
Our findings were out of harmony with both of these observations.
In 3 cases in which we did full-thickness autotranspiants, we
found no reaction, either in the healthy or fixed eruption skin,
that is, neither area reacted after an uneventful operative pro-
cedure. With such conflicting findings it is clear that further
investigation along these lines is needed. It is certainly not yet
justifiable to localize the site of the shock-tissue from experi-
mental observations so contradictory.
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The problem of refractoriness is a baffling one. The conten-
tion that this phenomenon is due to a local desensitization or
immunity has been advanced (7), and it is possible that this is
the correct interpretation. But in some cases at least this does
not seem to be the valid explanation. We refer to cases in which
a given dose fails to activate the lesion but an increased dose
evokes a prompt and characteristic response.
Is it .not possible, at least in some cases, that refractoriness may
be explained rather by an elevation of the threshold than by a
complete loss of the capacity to react?
We are not entirely certain whether a non-specific activation
may not at times be observed—in 2 of our cases, what appeared
to have been an activation by bismuth was seen. We are unable
to decide definitely that this was real or that the activation was
only the remains of a specific reaction just prior to the apparent
bismuth activation. Sulzberger (7), and Abramowitz and Russo
(12) have mentioned similar cases with local polyvalent sensi-
tivity, but we believe that instances of this sort must be quite rare.
Although fixed eruptions from tryparsamide have been reported
(Robinson (13), Kemp (14)), we have not encountered a case,
nor have we been able to activate any of our cases with trypars-
amide, in spite of repeated attempts with maximal doses. How-
ever, we can say that in many cases activation was produced by
other pentavalent arsenicals (acetarsone, aldarsone).
Not one instance has been encountered with a severe systemic
reaction of the type occasionally observed with extensive phenol-
phthalein fixed eruptions, in which an anaphylactoid reaction
with collapse may occur. In fact constitutional symptoms, such
as fever, nausea and vomiting and chills, have not been seen,
except in one patient who had fever and chills accompanying a
severe bullous reaction.
An all-important observation is that not a single patient de-
veloped one of the major arsenical dermatitides, in spite of the
continuance of arsenotherapy, many of the patients receiving
from 10 to 30 doses of the arsenical after the appearance of the
fixed eruption. In fact no other type of eruption, aside from
new lesions of the fixed eruption variety was seen.
From table 1 it can be seen that certain trivalent arsenicals
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activate less frequently than others, and therefore treatment,
where needed, may be continued with less difficulty by changing
to one of these.
SUMMARY
1. Sixty-nine patients, receiving organic trivalent arsenicals,
developed fixed eruptions—of these, 68 had arsenical fixed erup-
tions, and one of these had a double sensitivity to arsenicals and
phenolphthalein. One was sensitive only to antipyrine, and not
to the arsenicals.
2. Race is an important predisposing factor—79% occurred
in negroes, 19% in whites and 2% in the yellow race.
3. Lesions are most common on the face, and are also observed
over the entire body but not on the scalp, palms, and soles.
The mucous membrane of the mouth was involved in two cases.
4. In descending order of frequency, the precipitating drugs
were arsphenamine, neoarsphenamine, silver arsphenamine,
mapharsen and trisodarsen.
5. Lesions produced by one trivalent drug may be activated
by other trivalent drugs, and also by some pentavalent drugs.
6. Activation has only been seen when the drug is given by
the intravenous, oral or intramuscular routes. Patch tests and
iontophoresis have been consistently negative..
7. Successful full-thickness autotranspiants in 3 patients failed
to react when the drug was re-administered.
8. In spite of continued arsenotherapy, no case of exfoliative
dermatitis or any other type of arsenical dermatitis was observed
in the patient having fixed eruptions.
9. Since all trivalent arsenicals do not produce the fixed reac-
tions with equal frequency, it is possible to continue therapy
uneventfully by a change of arsenical (see table).
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DISCUSSION
D. SAMUEL M. PECK, New York City: I think this paper is a very important
contribution because we have so many cases gathered together. This has given
us an excellent opportunity to see many points developed by eminent observers,
but not previously coordinated because of lack of material.
In fixed eruptions we have perhaps a type reaction. Some patients show a
tendency to develop urticaria; others eczema; here we have a syndrome which is
quite another type.
Histology clearly demonstrates that both the epidermis and the blood vessels
in the cutis, especially those below the epidermis play a role in the formation of a
fixed eruption. This may explain the differences in the results obtained in trans..
plant experiments because since both the epidermis and blood vessels are con-
cerned the thickness of graft is important.
What is apparently normal skin clinically beyond the margin of the affected
area, is seen histologically to be still a drug eruption, but so reduced quantita-
tively that it is not macroscopically visible. This of course is the basis for
marginal re-elicitation.
DR. E. WILLIAM ABRAMOWITZ: For any group of investigators to have col-
lected sixty-nine cases of this particular type of eruption from arsphenamines
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is an unusual feat. This outnumbers all reports in the entire literature since
Naegeli in 1917 (Cor.-Bl. f. Schweiz aertzte, 47: 1291, 1917) first called attention
to such lesions. Chargin in 1923 stated that he had already seen three such
cases (Arch. Dermat. & Syph., 8: 110, 1923). Yet until comparatively recently
such lesions were usually considered mostly due to other drugs like antipyrine
and phenolphthalein. The complete list of drugs reported to have caused fixed
lesions totals twenty (Arch. Dermat. & Syph., 41: 707 (April) 1940). Not only
these but other agents like vaccines, liquors, karaya gum, foods, physical exer-
tion, psychic stress, metabolites, menstrual disturbances may also be included.
In fact, I believe that any substance, organic or inorganic may cause this
type of eruption, and it is necessary to go into a detailed history of such cases
to find out the particular cause. In some cases, polysensitivity to several of
these agents may be present.
With such a wealth of material it might be possible to answer some puzzling
questions. Is arsenic found and in what form in the fixed lesions from that drug?
Is it possible to cause a flare up of such lesions by applying or injecting a
particular arsenical compound to the affected area?
In cases of polysensitivity, which of these drugs or other agents can be found
in the affected areas?
Is there a contraindication to the use of the drug in case a fixed eruption
develops?
Can it be prevented—and how?
The term "fixed" in conjection with these eruptions is confusing. It indi-
cates something of a permanent nature which a fixed eruption is not. A more
suitable term is required to express the tendency to recurrence in the previously
affected areas: a term that that indicates also that the eruption will disappear
permanently when the cause is removed.
Dn. J. GARDNER HOPKINS, New York City: There are two points I would
like answered:
1. Did the patients who reacted to the two drugs react in precisely the same
areas to the two drugs?
2. Did the patients who reacted with urticaria always react with urticaria,
or sometimes with urticaria and sometimes with erythema?
Da. FRANK E. C01tMIA, Montreal: As Dr. Peck stated, it has always been my
conception that these patients with fixed eruptions, particularly with the ars-
phenamines, may have sensitivity in either the epidermis or dermis.
I was surprised that all these patients had weakly positive tests. I am pre-
senting two such cases and one of these I considered to be a fixed eruption of the
dermatitic type, really eczematous in nature, recorded after successive injections
of neoarsphenamine. Patch test was locally positive, and I want to ask if the
patch test in fixe4 eruptions from the araphenamines may not be either positive
or negative, depending on the site and degree of sensitivity?
DR. SAMUEL AYERS, JR., Los Angeles: Of the two cases discussed by Dr.
Chargin showing a mucous membrane involvement, did the eruption in either
case involve the eye? We have recently encountered what we consider to be a
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fixed eruption with ocular involvement, although this has not yet been proven.
There were skin lesions in the axillae and on the thigh and chronic conjunctivitis
and keratitis involving one eye only.
Da. ERIcH URBACH, Philadelphia: I would like to point out the following: first,
that I have seen cases in which fixed eruptions increased in size, as well as one
case of localized neoarsphenamine dermatitis, in which we later observed a
generalized skin eruption. I feel that we are dealing, in the latter case, not
with a primary antigen, but with a secondary antigen, formed by the combination
of the drug with altered endogenous protein.
Investigations which are not yet completed have shown me that if we com-
bine phenolphthalein with serum or skin of the phenolphthalein-sensitive pa-
tient, it will produce a positive skin reaction.
Many investigators have not obtained positive reactions with the auto-trans-
plantation method of Naegeli. I believe this depends on the time at which it is
done. Doctor Knowles of Philadelphia obtained a negative reaction at one time
and a positive reaction at another time in the same patient. It seems to de end
on when the graft is transplanted.
I have seen about three instances where we were able to deallergize this kind
of fixed eruption by the so-called deallergization method.
DR. Lows CHARGIN, New York City: In connection with Dr. Peck's remarks,
it is of interest to observe that the reaction was almost as marked in the sub-
clinical area as in the clinical area. This perhaps accounts for the reaction that
takes place at the border on readministration of the drug.
In regard to the remarks of Dr. Abramowitz, I have already stated that I
believe that these reactions are specific, although I must admit having seen
two instances in which bismuth seemed to have activated the areas. This may
have been due to the fact that the injection of bismuth followed so closely the
administration of arsenic that it was difficult to tell whether the bismuth really
activated the process.
One Chinese patient was convinced that the eruption was activated by some
Chinese food, but on study this was found to be erroneous.
In answer to Dr. Hopkin's question, we had one patient who exhibited a
double sensitivity; the phenolphthalein eruption was located on the right side
of the neck and right arm, while the arsphenamine eruption was scattered on
other areas of the body; and repeated testing demonstrated this specific double
reaction. In the patient who exhibited the urticarial eruption, it was limited
to the face and was not pigmented.
In answer to the question of Dr. Cormia, we believe that the patch test is
negative because the typical fixed eruption is not eczematous in nature.
As to Dr. Ayre's question, mucous membrane lesions appeared in one patient
who had a generalized eruption, and three patients reacted to arsphenamine only
on the lower lip, tongue, and mucous membrane. Conjunctival reactions were
observed by Naegeli and Jadassohn.
Dr. Urbach's question regarding transplant: we can state that in one instance
the lesion was transplanted while still active, yet gave no reaction on retesting.
